Monte Rosa publishes corporate presentation on targeted protein degradation pipeline and molecular glue degraders
GLUE•Program updates and trial timelines
- Novartis-led MRT-6160 (DDY391) showed over 90% VAV1 degradation in Phase 1; a Phase 2a/b Sjögren’s study is active.
- MRT-8102 interim Phase 1 data showed about 80-90% NEK7 degradation; Phase 2 starts in H2 2026 for elevated atherosclerotic risk.
- MRT-2359 combination data in AR-mutant mCRPC included a 100% PSA response rate; Phase 2 MODeFIRe-1 starts in 3Q 2026.
Financial runway and collaboration payments
Cash runway is guided into 2029; collaboration payments totaled about $350 million in three years with potential for over $400 million in 24 months.
Corporate presentation highlights pipeline progress
Monte Rosa highlighted three clinical molecular glue degrader programs with Phase 2 trials starting in 2026 across immunology, inflammation, and oncology.
